Miscarriage, Recurrent

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Grifols
GrifolsNEW YORK, NY
1 program
Gamimune N or Gamunex 10%N/A1 trial
Active Trials
NCT00606905CompletedEst. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GrifolsGamimune N or Gamunex 10%

Clinical Trials (1)

NCT00606905GrifolsGamimune N or Gamunex 10%

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Start: Nov 1999Est. completion: Jan 2010
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space